Cooper Companies (COO) Stock Forecast & Price Target

Cooper Companies is viewed positively because its core eyecare franchise combines durable leadership in contact lenses with a broad specialty portfolio, while CooperSurgical adds exposure to fertility and women’s health markets that can support balanced mid-single-digit organic growth. The company has also shown operating discipline, with revenue of $1.082B up 5% organic, adjusted EPS of $1.21 beating consensus, and an operating margin of 26.3% aided by SG&A leverage, even as gross margin held strong at 66.7%. Management’s increased $3B repurchase authorization, higher FY26 FCF guidance of $650M, and ongoing strategic review around CSI all reinforce the case for shareholder value creation and high-single-digit or better EPS growth.

Cooper Companies is facing a negative outlook because both segments are showing slower-than-expected growth, with F3Q26 revenue of $1.066 billion missing consensus and adjusted EPS of $1.15 only meeting estimates after tariff refunds. CooperVision was especially weak, as US channel inventory de-stocking, APAC softness, and legacy product declines left organic growth flat and forced FY26 revenue guidance down to $2.828-$2.842 billion, while management also cut consolidated FY26 EPS guidance to $4.51-$4.55. CooperSurgical was more resilient but still slowed to 3% organic growth, as softer capital equipment sales offset fertility strength, and the combination of slower EPS growth and a higher FY27 tax rate signals limited near-term earnings leverage.